Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kahn

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
The Journal of the American Osteopathic Association|December 1, 1984
Irreversible neurologic degeneration secondary to vitamin B12 deficiency without anemia: report of a caseB M Krein, J Troncoso, S B Kahn, et al.
Leukemia Research|January 1, 1979
Myeloproliferative disorders: II CML: clonal evolution and its role in managementI Brodsky, K E Fuscaldo, S B Kahn, et al.
British Journal of Haematology|May 1, 1971
Fibrinogen survival with [75Se]Selenomethionine during L-asparaginase therapyI Brodsky, S B Kahn, G Vash, et al.
Journal of Cardiothoracic Anesthesia|December 1, 1988
Case conference. A 60-year-old black woman with a small cell carcinoma of the lung develops a superior vena cava syndromeD A Plut, R S Wilson, A C Moncure, et al.
British Journal of Haematology|March 1, 1970
Simultaneous fibrinogen and platelet survival with (75Se)selenomethionine in man. Studies in diseases with normal coagulation and in hepatocellular disease with abnormal coagulationI Brodsky, N H Siegel, S B Kahn, et al.
American Journal of Clinical Oncology|February 1, 1987
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology GroupS B Kahn, A Spiers, W H Knospe, et al.
Haematologica|August 1, 1981
Myeloproliferative disorders: III. CML: Further studies on the role of cytogenetics in diagnosis, prognosis and managementK E Fuscaldo, I Brodsky, S B Kahn, et al.
Clinical Nephrology|November 1, 1992
RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapyA B Schwartz, S B Kahn, B Kelch, et al.
American Journal of Clinical Oncology|August 1, 1983
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemiaS B Kahn, R Sklaroff, J Lebedda, et al.
Series Haematologica (1968)|January 1, 1975
Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapyI Brodsky, K E Fuscaldo, S B Kahn, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
The Journal of the American Osteopathic Association|December 1, 1984
Irreversible neurologic degeneration secondary to vitamin B12 deficiency without anemia: report of a caseB M Krein, J Troncoso, S B Kahn, et al.
Leukemia Research|January 1, 1979
Myeloproliferative disorders: II CML: clonal evolution and its role in managementI Brodsky, K E Fuscaldo, S B Kahn, et al.
British Journal of Haematology|May 1, 1971
Fibrinogen survival with [75Se]Selenomethionine during L-asparaginase therapyI Brodsky, S B Kahn, G Vash, et al.
Journal of Cardiothoracic Anesthesia|December 1, 1988
Case conference. A 60-year-old black woman with a small cell carcinoma of the lung develops a superior vena cava syndromeD A Plut, R S Wilson, A C Moncure, et al.
British Journal of Haematology|March 1, 1970
Simultaneous fibrinogen and platelet survival with (75Se)selenomethionine in man. Studies in diseases with normal coagulation and in hepatocellular disease with abnormal coagulationI Brodsky, N H Siegel, S B Kahn, et al.
American Journal of Clinical Oncology|February 1, 1987
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology GroupS B Kahn, A Spiers, W H Knospe, et al.
Haematologica|August 1, 1981
Myeloproliferative disorders: III. CML: Further studies on the role of cytogenetics in diagnosis, prognosis and managementK E Fuscaldo, I Brodsky, S B Kahn, et al.
Clinical Nephrology|November 1, 1992
RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapyA B Schwartz, S B Kahn, B Kelch, et al.
American Journal of Clinical Oncology|August 1, 1983
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemiaS B Kahn, R Sklaroff, J Lebedda, et al.
Series Haematologica (1968)|January 1, 1975
Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapyI Brodsky, K E Fuscaldo, S B Kahn, et al.
Pageof 5